Due to the coronavirus epidemic, along with the lack of any financial assistance from the federal government, Garden State lawmakers resorted to adopting an interim state Budget for the period of July 1, 2020 through Sept. 30, 2020. In Sept., the Assembly and Senate Budget Committees accepted written public comments on fiscal year proposals covering Oct. 1, 2020 through June 30, 2021. Our agency, as well as, a number of our volunteer Advocates, submitted comments. The following is the NCADD-NJ organizational testimony:
The National Council on Alcoholism and Drug Dependence – NJ
(NCADD-NJ) is an incorporated non-profit organization operating in the Garden
State since 1982. NCADD-NJ works in partnership with, and on behalf of,
individuals, families, and communities affected by alcoholism and drug
dependence, to promote recovery. We have been working for more than thirty five
years to reduce the stigma and discrimination associated with addictive
illness. We have been strong advocates for public policies that increase access
to quality treatment and recovery services.
NCADD-NJ also operates the Substance Abuse Initiative and
Behavioral Health Initiative (SAI/BHI) to help implement the Work First New
Jersey welfare-to-work program funded by the NJ Dept. of Human Services. The
goal of the SAI/BHI is to eliminate addiction as a barrier to employment. The
NJ Division of Family Development funds our Family Violence Option (FVO)
project. The purpose of the FVO program is to afford protection to domestic
violence victims who are receiving General Assistance or Temporary Assistance
to Needy Families help.
We also provide substance misuse assessments for youth under
the supervision of the NJ Juvenile Justice Commission. This assessment further
includes level of care placement recommendations.
The present day description of the one-two punch of COVID-19
and addictions is as a crisis wrapped in a crisis. The coronavirus pandemic has
exacerbated the psychological factors that are involved in substance use
behavior. The medical journal PSYCHIATRY RESEARCH (Aug. 18, 2020) noted that
the social isolation, economic hardship, worry, fear, and disruption of normal
activities have resulted in increased drug misuse among those with existing
addiction disorders, along with a rise in use among former abstainers.
Combine this with capacity limitations, growing waitlists, and reduced hours at
many addiction treatment programs and one sees what could have long been
expected – a nearly 20% increase of drug overdoses, according to a University
of Baltimore study last month. Overdose deaths in New Jersey were averaging
around 3,000 per annum for the past several years before COVID-19. It is
blatantly obvious the State must find the resources to, not just maintain past
levels of funding, but to enhance the response to an escalating need.
We are encouraged to see the Dept. of Human Services
continue to do more with less as, among other initiatives, it has sustained its
naloxone (opioid overdose reversal drug) free distribution to individuals,
police depts., libraries, and homeless shelters effort, along with the launch
of a program to train EMS first responders on interacting with patients
following treatment from a suspect opioid overdose and linking patients to
needed services.
A final observation – In a report issued by the American
Medical Association’s (AMA) Opioid Task Force (July 28, 2020), it was
determined that, although opioid prescriptions decreased in the last year, the
use of illicit drugs has gone up. This leaves for a future debate the question
of whether restricting access to prescribed and regulated medications, rather
than decreasing drug misuse, isn’t instead, driving up customers for the
illegal trade? In the Governor’s proposed nine-month Budget, he included
anticipated revenue from an “opioid tax.” Our belief is that this may well have
the unintended and ironic consequence of hurting the effort to mitigate the
worsening drug addiction crisis in our state. Two of the drugs utilized as part
of a medication assisted treatment (MAT) regimen to treat addictions, are
methadone and buprenorphine. Both contain a certain amount of opioid medication
(the former 10% and the latter 85%). A tax on their use will certainly make
them more expensive, if not entirely inaccessible. Attaching extra costs to
therapies that help people to heal seems never to be a good idea. Making it
more burdensome for individuals seeking relief from chronic pain and addiction
disorders would be foolish.
